Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care-Reference-Cited by-同舟云学术

Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care

Published:2024-01-25 Issue:6 Volume:130 Page:961-969
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Blanchet Benoit,Xu-Vuilard Alexandre,Jouinot Anne,Puisset Florent,Combarel David,Huillard Olivier^ORCID,Le Louedec Félicien,Thomas Fabienne,Teixeira Marcus,Flippot Ronan,Mourey Loic,Albiges Laurence,Pudlarz Thomas,Joly Charlotte,Tournigand Christophe,Chauvin Jonathan,Puszkiel Alicja,Chatelut Etienne,Decleves Xavier,Vidal Michel,Goldwasser François,Oudard Stéphane,Medioni Jacques,Vano Yann-Alexandre

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41416-024-02585-y.pdf

Reference30 articles.

1. Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Prim. 2017;3:17009.

2. Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N. Engl J Med. 2015;373:1814–23.

3. Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N. Engl J Med. 2021;384:829–41.

4. Buil-Bruna N, López-Picazo J-M, Martín-Algarra S, Trocóniz IF. Bringing model-based prediction to oncology clinical practice: a review of pharmacometrics principles and applications. Oncologist. 2016;21:220–32.

5. Schmidinger M, Danesi R, Jones R, McDermott R, Pyle L, Rini B, et al. Individualized dosing with axitinib: rationale and practical guidance. Future Oncol Lond Engl. 2018;14:861–75.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population Pharmacokinetics of Cabozantinib in Metastatic Renal Cell Carcinoma Patients: Towards Drug Expenses Saving Regimens;Clinical Pharmacokinetics;2024-06